BioSolutions Clinical Research Center

CURRICULUM VITAE

SIGNATURE:	Thomas C. Adamson III	**DATE:**	08/19/2019
NAME: **TITLE:**	Thomas C. Adamson, III, MD, FACP, CPE Investigator	**DATE UPDATED:**	August 2019

RESEARCH SITE ADDRESS & PHONE:

Main Office: BioSolutions Clinical Research Center 5565 Grossmont Center Dr, Bldg. 3, Suite 253 La Mesa CA 91942	Office: (619) 637-0770 Fax: (619) 713-0156 Email: dradamson@biosolutionsresearch.com

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
University of Michigan, Ann Arbor, MI	Chemistry	1969-1972	Bachelor of Science with High Distinction
University of Michigan Medical School, Ann Arbor, MI	M.D.	1973-1977	Medicine
Henry Ford Hospital, Detroit, MI	Residency	1977-1980	Internal Medicine
Scripps Clinic and Research Foundation, La Jolla, CA	Fellowship	1980-1982	Rheumatology
American College of Physician Executives	CPE	1994-2001	Certified Physician Executive

POSITIONS AND EMPLOYMENT:

2019-Present	Investigator, BioSolutions Clinical Research Center, La Mesa, CA
1982-2019	Division of Rheumatology (Chief 1982-2002) Sharp Rees-Stealy Medical Group, San Diego, CA
1987-2001	Director of Managed Care, Sharp Rees-Stealy Medical Group, San Diego, CA
1973	Laboratory Assistant, Department of Biological Chemistry, University of Michigan, Ann Arbor, MI
1973	Teaching Fellow, Department of Chemistry, University of Michigan, Ann Arbor, MI

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
American Board of Internal Medicine Diplomat in Internal Medicine	1980	Internal Medicine
Diplomat in Rheumatology	1982	Rheumatology

CLINICAL RESEARCH EXPERIENCE:

Associate Investigator in "A Double-Blind Placebo Controlled Comparison of Tiamenidine and Clonidine in Mild or Moderate Hypertension Double-Blind and One Year Open-Label." Hoechst-Roussel

.

Associate Investigator in "Cardizem in Hypertension--Double-Blind, Open-Label." Marion.

Associate Investigator in "Heart Attack Primary Prevention in Hypertension: International Cooperative Study Group on Beta Blockers vs. Diuretics in Hypertension." ICI, Stuart.

Principal Investigator in "A Triple-Blind Comparison of Fenoprofen Calcium Enteric Coated 600 mg. with Fenoprofen Non-Enteric Coated 600 mg. in Patients with Large Joint Osteoarthritis." Lilly

Principal Investigator in "An Open-Label, Non-Comparative, Multicenter Study of the Safety and Efficacy of CL 284,635 in the Treatment of Acute Urinary Tract Infections." Lederle,

Principal Investigator in "An Open-Label, Non-Comparative, Multicenter Study of the Safety and Efficacy of CL 294,635 in the Treatment of Acute Upper Respiratory Infections in Adult Patients."

Associate Investigator in "A Multi-Investigator, Double-Blind, Single Dose Evaluation of the Analgesic Efficacy of Nuprin vs. Tylenol vs. Placebo in the Treatment of Patients with Tension Headaches." Brostol-Meyers.

Principal Investigator in "A Dose-Range Finding Study of RO31-2848 (Ace-Inhibitor) in Patients with Uncomplicated Essential Hypertension." Hoffman-LaRoche.

Associate Investigator in "Multi-Investigation, Double-Blind, Cross-Over Evaluation of the Analgesic Efficacy of Single Doses of Excedrin, Extra-Strength Tylenol and Placebo in the Treatment of Patients with Acute Muscle-Contraction Headaches." Bristol-Meyers.

Associate Investigator in "Triamterene for Dose-Ranging Study of Hypertensive Patients for Reversal of Hypokalemia Induced by 25 mg. of Hydrochlorothiazide." Smith, Kline and French.

Associate Investigator in "A Comparative Study of Microx vs. Dyazide in the Treatment of Mild Hypertension." Pennwalt.

Associate Investigator in "Evaluation of Efficacy and Safety of Cilazapril in Combination with HCTZ in Patients with Essential Hypertension." Hoffman-LaRoche.

Associate Investigator in "A Phase III Study of the Effects of Sertraline on Body Weight in Obese, Type II Diabetic Patients." Pfizer.

Associate Investigator in "A Phase III Study of the Effects of Sertraline on Body Weight in Obese, Type II Diabetic Patients: An Extension." Pfizer.

Principal Investigator in "Multiple Dose Safety and Efficacy Comparison of Two Doses of Tifurac Sodium and Placebo in the Symptomatic Treatment of Active Rheumatoid Arthritis." Syntex.

Associate Investigator in a "Multi-Investigator, Double-Blind, Cross-Over Evaluation of the Analgesic Efficacy of Single Doses of Aspirin-Free Excedrin, Extra Strength Tylenol and Placebo in the Treatment of Patients with Acute Muscle Contraction (Tension) Headaches." Bristol-Meyers.

Associate Investigator in "Evaluation of the Efficacy and Safety of Cilazapril in Combination with HCTZ in Patients with Essential Hypertension." Hoffman-LaRoche.

Associate Investigator in a "Double-Blind Parallel Study Designed to Compare the Effects of Sertraline and Placebo on the Obese patient with Hypertension." Pfizer.

Associate Investigator in "A Double-Blind, Placebo-Controlled Comparison of 6.25 mg., 12.5 mg., 25.0 mg. and 50.0 mg. UID Carvedilol in Patients with Mild to Moderate Hypertension." Smith, Kline, and French.

Principal Investigator in "A Double-Blind, Placebo-Controlled Comparison of 6.25 mg., 12.5 mg., and 50.0 mg. UID Carvedilol in Patients with Mild to Moderate Hypertension." Smith, Kline, and French.

Principal Investigator in "Multiple Dose Safety and Efficacy Comparison of Naproxen Standard Tablets to Naproxen Controlled Release Tablets in Patients with Arthritis." Syntex.

Principal Investigator in "A One-Year Open Label Positive Controlled Trial of Carvedilol Administered Once Daily in patients with Mild to Moderate Hypertension." Smith, Kline, and French.

Associate Investigator in "A One-Year Open Label Positive Controlled Trial of Carvedilol Administered Once Daily in patients with Mild to Moderate Hypertension." Smith, Kline, and French.

Principal Investigator in "Double-Blind Placebo-Controlled Efficacy and Safety Study of Ditropan and RTM SR Tablets for the Treatment of Symptoms of Bladder Instability of Non-Neuropathic Origin." Marion.

Associate Investigator in a "Multicenter, Placebo-Controlled Study Evaluating the Safety and Comparing the Anti-Hypertensive Effect of Cilazapril in Combination with HCTZ vs. Effect of Cilazapril or HCTZ." Hoffman-LaRoche,

Associate Investigator in "A Randomized Double-Blind Parallel Group Study Comparing the Efficacy and Safety of Placebo, Bisoporol 5 mg., HCTZ 6.25 mg., and HCTZ 25 mg, given Once Daily in Patients with Mild to Moderate Essential Hypertension." American Cyanamid.

Principal Investigator in "A Second Year, Open-Label Trial of Carvedilol Administered Once Daily to Patients with Mild to Moderate Hypertension." Smith, Kline, French.

Associate Investigator in "A Second Year, Open-Label Trial of Carvedilol Administered Once Daily to Patients with Mild to Moderate Hypertension." Smith Kline, and French.

Principal Investigator in "A Multicenter Double-Blind, Forced-Dose Titration, Safety and Tolerance Study of Oral BRL 38227 in Hypertensive Patients." SmithKline Beecham.

Associate Investigator in "Double-Blind Placebo-Controlled Evaluation of the Efficacy and Safety of 600 mg. Trental Tablets in Patients with Intermittent Claudication." Hoechst-Roussel.

Associate Investigator in "Multiple Dose Comparison of Combivent with its Components in a 12-Week, Parallel Study in Adults with Obstructive Pulmonary Disease." Boehringer Ingelheim.

Associate Investigator in "Nazatidine vs. Placebo in Preventing NSAID - Associated Ulcers." Lilly.

Principal Investigator in "The Efficacy and Safety of Misoprostol for the Prevention of NSAID-Induced GI Complications." Searle.

Principal Investigator in "A Randomized Double-Blind, Multicenter, Withdrawal Study to Evaluate the Safety and Efficacy of Two Dose Levels of Moexipril During a 12 week Treatment Period Followed by a 12 Week Placebo-Controlled Withdrawal Period in Patients with Mild to Moderate Essential Hypertension." Schwarz.

Associate Investigator in "Efficacy and Tolerance of Extended Release Felodipine in Adult Patients with Mild to Moderate Uncomplicated Essential Hypertension." Merck.

Associate Investigator in "Double-Blind Placebo Controlled Evaluation of the Efficacy and Safety of 600 mg. Trental Tablets in Patients with Intermittent Claudication.".

Principal Investigator in "A Double-Blind Comparison of Nabumetone and Indomethacin in the Treatment of Patients with Moderate to Severe Osteoarthritis." SmithKline Beecham.

Principal Investigator in "Phase I/II Open Label Safety and Dose Ranging Study of Beta Prime-RA Vaccine in Rheumatoid Arthritis (RA) Patients." Immune Response.

Associate Investigator in ."A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo or Rheumatoid Arthritis." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo in the Treatment of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric Ulcers in Patients with Osteo or Rheumatoid Arthritis and No History of Gastric or Duodenal Ulcer." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo for Maintenance of Healed Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric and Duodenal Ulcers in Patients with Osteo or Rheumatoid Arthritis." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric and Duodenal Ulcer in Patients with Osteo or Rheumatoid Arthritis and No History of Gastric or Duodenal Ulcer." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug Associated Gastric and Duodenal Ulcers in Patients with Osteo or Rheumatoid Arthritis and a History of Gastric or Duodenal Ulcer." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo in the Treatment of Aspiritn or Nonsteroidal Anti-inflammatory Drug-Associated Duodenal Ulcers in Patients with Osteo or Rheumatoid Arthritis and No History of Gastric or Duodenal Ulcer." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo for Maintenance of Healed Aspirin or Nonsteroidal Anti-Inflammatory Drug-Associated Gastric and Duodenal Ulcers in Patients with Osteo or Rheumatoid Arthritis." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BId, Ranitidine 150 mg. BID and Placebo for Prophylaxis of Aspirin of Nonsteroidal Anti-Inflammatory Drug-Associated Gastric and Duodenal Ulcer in Patients with Osteo or Rheumatoid Arthritis and no History of Gastric or Duodenal Ulcers." Glaxo.

Associate Investigator in "A Comparison of Ranitidine 300 mg. BID, Ranitidine 150 mg. BID and Placebo for Prophylaxis of Aspirin or Nonsteroidal Anti-Inflammatory Drug-Associated Gastric and Duodenal Ulcers in Patients with Osteo or Rheumatoid Arthritis and a History of Gastric or Duodenal Ulcer." Glaxo

Principal Investigator in "Phase I/II Open Label Safety and Dose ranging Study of Beta Prime-RA Vaccine in Rheumatoid arthritis Patients." Immune Response.

Principal Investigator in "Protocol for Phase I Open Label Safely and Dosing Ranging Study of A1205 Therapeutic Vaccine in Rheumatoid Arthritis Patients." Immune Response.

Principal Investigator in "A Randomized, Double-Blind, Placebo-Controlled, Factorial design Dose-Response Study of Temocapril HCL Alone or in Combination with HCTZ in Patients with Mild to Moderate Essential Hypertension." Sanyko.

Principal Investigator in "Phase I Open-Label Safety and Dosing Ranging Study of A1204 Therapeutic Vaccine in Rheumatoid Arthritis Patients." Immune Response.

Associate Investigator in "Trial of Usual Care for Hypertension (TOUCH): Cozaar and Hyzaar versus Usual Care in the Treatment of Patients with Hypertension in a Managed Care setting--Physician Pilot Period." Merck.

Principal Investigator in "An Evaluation of the Analgesic Efficacy and safety of Ultram compared to Ibuprofen in Subjects with Chronic Pain of Osteoarthritis." Ortho-McNeil.

Associate Investigator in "Trial of Usual Care for Hypertension (TOUCH): Cozaar and Hyzaar versus Usual care in the Treatment of Patients with Hypertension in a Managed Care Setting--Comparative Treatment Period." Merck.

Principal Investigator in "Double-Blind, Phase II Study of IR501 Therapeutic vaccine in Rheumatoid arthritis (RA) Patients, Study IR501-223." Immune Response Corporation.

Principal Investigator in "The Antihypertensive efficacy and safely of RO 40-5967 in Comparison with Amlodipine in Patients with Mild to Moderate Essential Hypertension." Hoffmann-La Roche.

Principal Investigator in "Evaluation of the Safety and Efficacy of adding Candesartan Cilestil (8 to 16 mg) to Hydrochlorothiazide in the Treatment of Patients with severe Hypertension: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study with an Open-Label, Long-Term Extension." Astra/Merck.

Principal Investigator in "An Active, Comparator-Controlled, Parallel-Group, One Year, Double blind Study, Conducted Under In-House Blinding Conditions, to Assess the Safety and Efficacy of MK-0966 versus Doclofenac Sodium in Patients with Osteoarthritis of the Hip or Knee." Merck,

Associate Investigator in "A Prospective, Double-Blind, Randomized, Parallel Study of the Effects of the Non-steroidal Anti-Inflammatory Drug Indomethacin on the Antihypertensive Response to Losartan versus Captopril in Patients with Essential Hypertension." Merck.

Principal Investigator in "The First Double-Blind, Active Comparator-Controlled Extension of an Active Comparator-Controlled, One Year Study to Assess the Safety and Efficacy of MK-0966 Versus Diclofenac in Patients with Osteoarthritis of the Knee or Hip." Merck.

Principal Investigator in "An Open-Label, Long-Term Safety and Activity Study of IR501 Therapeutic Vaccine in Patients with Active Rheumatoid Arthritis." Immune Response Corporation.

Principal Investigator in "A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0966 12.5 mg vs. Nabumetone 1000 mg in Patients with Osteoarthritis of the Knee." Merck.

Associate Investigator in "A Multi-Center, Open-Label Study Evaluating the Safety andTolerability of Tramadol Hydrochloride Controlled-Release Tablets in Patients with Chronic Pain." Purdue Pharmaceuticals.

Principal Investigator in "TROPHY Trial Of Preventing Hypertenion : A Randomized, Double-Blind, Placebo-controlled, Multicenter, Long-Term Trial Preventing Hypertention using Candesartan Cilexetil 16 mg in Patient with Hight Normal Blood Pressure." Astra.

Principal Investigator in "A Comparison of the Analgesic Efficacy and safety of Tramadol HCL/Acetamenophen Versus Placebo for the Treatment of a Painful Flare of Osteoarthritis." Ortho-McNeil.

Principal Investigator in "An Active-comparator and Placebo-controlled , Parallel-Group, Double-Blind, 52-week Study to Assess the Safety and Efficacy of MK-0663 in Rheumatoid Arthritis Patients." Merck.

Principal Investigator in "A Msulticenter, Randomized, Blinded, Placebo Controlled Study to Describe Long-term safety of Daily Subcutaneous Injections of Anakindra (r-metHulL-1ra) in Patient with Rheumatoid Arthritis." Amgen.

Principal Investigator in "Clinical Protocol for a Double-blind, Randomized, Parallel Group Comparison Study of the Safety of Celecoxib versus Rofecoxib in Treated Hypertensive Patients with Osteoarthritis (SUCCESS VII)." Searle.

Principal Investigator in "Clinical Protocol for a Double-Blind, Placebo-controlled, Randomized Six-week Comparison Study of the Efficacy of Valdecoxib 20 mg QD and Rofecoxib 25 mg QD in Relieving the signs and Symptoms of Osteoarthritis of the Knee." Pharmacia and Upjon.

Principal Investigator in "Study of Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Twice Daily Naproxen vs. Placebo in the Treatment of Asian-American Subjects with Osteoarthritis of the Knee." Pfizer.

Principal Investigator in "Protocol A945-1008: A 15-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Multi-Center Study of Neurontin (gabapentin) for Efficacy and Quality of Life in Patients with Painful Diabetic Peripheral Neuropathy." Pfizer.

Associate Investigator in "A Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study of the Safety and efficacy of Cyclosporine 0.05% Ophthalmic Emulsion Used Twice Daily for Six Months in Patients with Moderate to Severe Keratoconjuctivitis Sicca." Allergan.

Associate Investigator in "Protocol Number 285: A Comparative efficacy and safety Study of Nexium (esomeprazole magnesium) Delayed-release Capsule (40 mg qd and 20 mg qd) versus Ranitidine for Prevention of Gastric Ulcers Associated with Daily NSAID Use in Patients at Risk." Astra Zeneca.

Associate Investigator in "Protocol Number 289: a comparative efficacy and safety Study of Nexium (esometprazole magnesium) Delayed-Release Capsule (40 mg qd and 20 mg qd) versus Placebo for Prevention of Gastric Ulcers Associated with daily NSAID Use in Patients at Risk." Astra Zeneca.

Principal Investigator in "A Phase III Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral TMX-67 versus Allopurinol in Subjects with Gout." TAP.

Principal Investigator in "Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis." Merck.

Principal Investigator in "Double-Blind, randomized, Dose-Ranging, Parallel-Group Comparison of the efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCL ER) 100 mg, 200 mg, 300 mg and 400 mg with Placebo in the Treatment of Osteoarthritis of the Hip and/or Knee." Biovail.

Principal Investigator in "Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Two-Week Comparison Study of the Efficacy and Tolerability of Valdecoxib 10 mg QD and Rofecoxib 25 mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee." Pharmacia and Upjohn.

Principal Investigator in "A 13-Week, Multicenter, International, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Two Doses of COX 189 (200 mg and 400 mg o.d.) in Patients with Rheumatoid Arthritis using Naproxen (500 mg b.i.d.) as Comparator." Novartis Pharmaceuticals Protocol COX189A 2335.

Principal Investigator in " A Double-Blind, Randomized, Trial of Intra-Articular Injection of Hylagan® into the Glenohumeral Articular Space for the Treatment of Chronic Painful Shoulder with Limitation of Motion due to Glenohumeral Joint Osteoarthritis, Rotator Cuff Tear (Partial or Complete) and/or Primary or Secondary Adhesive Capsulitis – (HYLAGAN USE IN PAINFUL SHOULDER – HUPS)." Sanofi-Synthelabo Protocol L-8229 (HUPS).

Principal Investigator in "Humira Efficacy Response Optimization Study in Subjects with Active Rheumatoid Arthritis (HERO)." Abbott Laboratories Protocol No. M04-684.

Principal Investigator in "A Double-Blind, Randomized Trial of Intra-Articular Injections of 20mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis. (Three Injection Regime for Efficacy And Duration 20mg/2ml Dose: TREAD-20).", Sanofi-Aventis: Protocol L-9385.

Principal Investigator in "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis." Amgen Pharmaceuticals: Protocol AMG 108 20050168.

Principal Investigator in "Index for Rheumatoid Arthritis Measurement (InFoRM) Study:". Crescendo Bioscience.

Associate Investigator in "A Multi-Center, Randomized, Double-Blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment with Tocilizumab (TCZ), as a Mono-Therapy and in Combination with Methotrexate (MTX), Versus Methotrexate in Patients with Early, Moderate to Severe Rheumatoid Arthritis." Hoffman-LaRoche WA 19926.